Miheer
@miheerp.bsky.social
Heme/onc. Was never that into Twitter, so we’ll see if the skies stay blue. I guess I’ll start by posting info I find useful in everyday clinical practice. #MedSky #HemeSky #OncSky
Shoutout to whoever at Mayo made this graphic of the general myeloma treatment paradigm.
I’ve found it incredibly useful helpful to give the 10,000ft view at initial diagnosis.
#HemeSky #OncSky #mmsm
Source: www.mayoclinic.org/medical-prof...
I’ve found it incredibly useful helpful to give the 10,000ft view at initial diagnosis.
#HemeSky #OncSky #mmsm
Source: www.mayoclinic.org/medical-prof...
November 20, 2024 at 2:11 AM
Shoutout to whoever at Mayo made this graphic of the general myeloma treatment paradigm.
I’ve found it incredibly useful helpful to give the 10,000ft view at initial diagnosis.
#HemeSky #OncSky #mmsm
Source: www.mayoclinic.org/medical-prof...
I’ve found it incredibly useful helpful to give the 10,000ft view at initial diagnosis.
#HemeSky #OncSky #mmsm
Source: www.mayoclinic.org/medical-prof...
The most challenging thing for me in erythrocytosis/polycythemia workups has been thinking about all of the possible etiologies when the JAK2/CALR/MPL testing comes back negative.
This article is GOLD.
#HemeSky #MedSky
pubmed.ncbi.nlm.nih.gov/36966432/
This article is GOLD.
#HemeSky #MedSky
pubmed.ncbi.nlm.nih.gov/36966432/
JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management - PubMed
Advances in molecular hematology might result in better characterization of "idiopathic erythrocytosis" and expansion of the repertoire for germline mutations in hereditary erythrocytosis. Prospective...
pubmed.ncbi.nlm.nih.gov
November 13, 2024 at 11:24 PM
The most challenging thing for me in erythrocytosis/polycythemia workups has been thinking about all of the possible etiologies when the JAK2/CALR/MPL testing comes back negative.
This article is GOLD.
#HemeSky #MedSky
pubmed.ncbi.nlm.nih.gov/36966432/
This article is GOLD.
#HemeSky #MedSky
pubmed.ncbi.nlm.nih.gov/36966432/